Health

Developing Clinically Relevant Models for Evaluating Novel Therapies, Upcoming Webinar Hosted by Xtalks

Leave a comment


The speaker will also discuss the importance of selecting clinically relevant glioblastoma models that closely recapitulate human glioblastoma as well as specialized intracranial engraftment and dosing techniques.


TORONTO (PRWEB)

The blood-brain barrier (BBB) is a critical obstacle to developing brain-penetrant therapies for glioblastoma research and treatment. Orthotopic intracranial glioblastoma models (orthotopic means “the correct place”) are a next-generation platform that provide accurate preclinical data to inform lead candidate progression into the clinic.

During this free webinar, the featured speaker will reveal innovations in glioblastoma model development and the future of glioblastoma research, diving into critical issues affecting glioblastoma drug development and how to overcome them. Attendees will review an in-depth case study illustrating in vivo and in vitro approaches to model glioblastoma via 3D spheroid and intracranial orthotopic patient-derived xenograft (O-PDX) models. The speaker will also discuss the importance of selecting clinically relevant glioblastoma models that closely recapitulate human glioblastoma as well as specialized intracranial engraftment and dosing techniques.

Reserve your place in this webinar to learn about the future of glioblastoma research and how to overcome challenges with glioblastoma drug development.

Join Monika Buczek, PhD, Director, Business Development, Certis Oncology Solutions, for the live webinar on Wednesday, September 14, 2022, at 2pm EDT (11am PDT).

For more information, or to register for this event, visit The Future of Glioblastoma Research: Developing Clinically Relevant Models for Evaluating Novel Therapies.

ABOUT CERTIS

Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is “Oncology Intelligence™—highly predictive therapeutic response data derived from advanced biological models of cancer. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies. Certis partners with therapeutics developers to help close the problematic “translation gap” between preclinical studies and clinical trials. Through more clinically relevant, well-characterized and annotated models, advanced imaging technology and thoughtfully designed studies, Certis brings greater certainty to go/no-go development decisions.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Leave a Reply